Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Continuous Adductor Canal Block (CACB) Combined With İnfiltration Between the Popliteal Artery and Capsule of the Knee (iPACK) Block vs Continuous Adductor Canal Block Alone After Total Knee Arthroplasty

28. september 2026 oppdatert av: Furkan Tontu, Başakşehir Çam & Sakura City Hospital

Comparison of the Effects of iPACK Block Combined With Continuous Adductor Canal Block Versus Continuous Adductor Canal Block Alone on Postoperative Analgesia, Early Mobilization, and Length of Hospital Stay in Total Knee Arthroplasty Cases

This study compares the effects of adding an infiltration between the popliteal artery and capsule of the knee (iPACK) block to a continuous adductor canal block (CACB) versus continuous adductor canal block alone on postoperative analgesia, opioid consumption, early mobilization, and length of hospital stay in patients undergoing total knee arthroplasty. This is a prospective, randomized, double-blind study with 54 patients allocated 1:1 into two groups.

Studieoversikt

Detaljert beskrivelse

Severe postoperative pain occurs in up to 58% of patients after total knee arthroplasty. Peripheral nerve blocks are an effective component of multimodal analgesia, and the continuous adductor canal block (CACB) has become a preferred technique because it provides sensory blockade while sparing motor function of the quadriceps, allowing earlier ambulation compared to femoral nerve block. However, CACB does not address posterior knee pain, which can be targeted by the iPACK (infiltration between the popliteal artery and capsule of the knee) block, a technique that blocks terminal sensory branches of the tibial and peroneal nerves without motor blockade.

In this study, patients scheduled for total knee arthroplasty will be randomized 1:1 (using randomizer.org) to receive either CACB alone (Group 2) or CACB combined with a single-injection iPACK block (Group 1). CACB will be maintained via a perineural catheter connected to a patient-controlled analgesia (PCA) pump delivering 0.1% bupivacaine. Rescue analgesia will be provided with intravenous tramadol (50 mg, max 300 mg/day) when the numeric rating scale (NRS) pain score exceeds 4.

Pain scores (NRS 0-10), total analgesic and opioid consumption, hemodynamic parameters, time to first mobilization (assessed via the Timed Up and Go test), patient satisfaction, and length of hospital stay will be recorded at baseline and at 1, 3, 6, 12, and 24 hours postoperatively by an anesthesiologist blinded to group allocation, different from the anesthesiologist who performed the block.

Studietype

Intervensjonell

Registrering (Antatt)

54

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Istanbul
      • Başakşehir, Istanbul, Tyrkia (Türkiye), 34480
        • Basaksehir Çam Ve Sakura City Hospital, İstanbul, Türkiye
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Furkan TONTU, MD
        • Underetterforsker:
          • Muzaffer GENCER, MD
        • Underetterforsker:
          • Murat Y Mersin, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients of either sex
  • Aged 18 to 75 years
  • American Society of Anesthesiologists (ASA) physical status I, II, or III
  • Voluntary participation
  • Fully oriented and able to cooperate with postoperative assessments

Exclusion Criteria:

  • ASA physical status IV or V
  • Patients who decline to participate
  • Pediatric patients
  • Active infection at the block site
  • Chronic pain or regular analgesic use
  • Coagulation disorders
  • Inability to cooperate with postoperative pain assessment
  • Known allergy to local anesthetics
  • Neuropathy or myopathy in the operated extremity
  • Revision arthroplasty cases

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Group 1 (CACB + iPACK)

Continuous adductor canal block (catheter, PCA with 0.1% bupivacaine) plus a single-injection iPACK block (0.25% bupivacaine 20 mL)

Single injection of 0.25% bupivacaine 20 mL between the popliteal artery and posterior knee capsule, performed under ultrasound guidance

Perineural catheter placement in the adductor canal with PCA-delivered 0.1% bupivacaine (5-7 mL basal rate, 5 mL bolus, 30-min lockout) for 24 hours postoperatively

Aktiv komparator: Group 2 (CACB Alone)

Continuous adductor canal block alone (catheter, PCA with 0.1% bupivacaine)

Perineural catheter placement in the adductor canal with PCA-delivered 0.1% bupivacaine (5-7 mL basal rate, 5 mL bolus, 30-min lockout) for 24 hours postoperatively

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative Pain Score (Numeric Rating Scale)
Tidsramme: Baseline and postoperative hours 1, 3, 6, 12, and 24

Pain intensity assessed using the Numeric Rating Scale (NRS, 0-10; 0 = no pain, 10 = worst pain imaginable)

Baseline and postoperative hours 1, 3, 6, 12, and 24

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total Opioid Consumption
Tidsramme: Postoperative 24 hours

Total rescue analgesic (tramadol) consumption via intravenous (IV) administration

Postoperative 24 hours
Total Local Anesthetic Consumption
Tidsramme: Postoperative 24 hours

Total bupivacaine consumed via patient-controlled analgesia (PCA) pump

Postoperative 24 hours
Time to First Mobilization
Tidsramme: Postoperative 24 hours

Time to first unassisted ambulation/movement, assessed via the Timed Up and Go (TUG) test

Postoperative 24 hours
Length of Hospital Stay
Tidsramme: From surgery to discharge (up to approximately 1 week)

Number of days from surgery to discharge

From surgery to discharge (up to approximately 1 week)
Patient Satisfaction Score
Tidsramme: Postoperative 24 hours

Satisfaction rated on a 4-point scale (1 = not satisfied, 2 = Slightly satisfied, 3 = Satisfied, 4 = very satisfied)

Postoperative 24 hours
Systolic Blood Pressure
Tidsramme: Baseline and postoperative hours 1, 3, 6, 12, and 24

Systolic blood pressure measured in mmHg

Baseline and postoperative hours 1, 3, 6, 12, and 24
Diastolic Blood Pressure
Tidsramme: Baseline and postoperative hours 1, 3, 6, 12, and 24

Diastolic blood pressure measured in mmHg

Baseline and postoperative hours 1, 3, 6, 12, and 24
Mean Arterial Blood Pressure
Tidsramme: Baseline and postoperative hours 1, 3, 6, 12, and 24

Mean arterial blood pressure (MAP) measured in mmHg

Baseline and postoperative hours 1, 3, 6, 12, and 24
Heart Rate
Tidsramme: Baseline and postoperative hours 1, 3, 6, 12, and 24

Heart rate measured in beats per minute

Baseline and postoperative hours 1, 3, 6, 12, and 24
Peripheral Oxygen Saturation
Tidsramme: Baseline and postoperative hours 1, 3, 6, 12, and 24

Peripheral oxygen saturation (SpO2) measured as a percentage

Baseline and postoperative hours 1, 3, 6, 12, and 24
Block-Related Complications
Tidsramme: Throughout study participation (up to 24 hours postoperatively)

Incidence of complications associated with the regional block techniques (e.g., nerve injury, infection)

Throughout study participation (up to 24 hours postoperatively)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Furkan TONTU, MD, BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR HASTANESİ
  • Studieleder: Muzaffer GENCER, MD, BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR HASTANESİ
  • Studieleder: Murat Y Mersin, MD, BAŞAKŞEHİR ÇAM VE SAKURA ŞEHİR HASTANESİt

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

25. september 2026

Primær fullføring (Antatt)

4. desember 2026

Studiet fullført (Antatt)

11. desember 2026

Datoer for studieregistrering

Først innsendt

15. september 2026

Først innsendt som oppfylte QC-kriteriene

28. september 2026

Først lagt ut (Faktiske)

1. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared beyond what is reported in publications resulting from this study.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere